Physician profile
Joel E Portnoy
NPI 1083878102
$6,760.97
in general payments reported to CMS, 2019-2025
36 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $190 · 2021: $272 · 2022: $1,151 · 2023: $1,613 · 2024: $1,539 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,307.28 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,053.84 | 2021-2025 | Nucala |
| Optinose US, INC. | $1,046.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $939.78 | 2022-2025 | Dupixent |
| Inspire Medical Systems, INC. | $289.91 | 2023-2025 | Inspire |
| Neurent Medical Limited | $243.58 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Stryker Corporation | $219.54 | 2019-2025 | Clarifix Cryotherapy Device, Xerogel Nasal/Epistaxis 2 Pack, Xpress Ent Dilation System |
| Grifols USA, LLC | $196.17 | 2020-2025 | Xembify |
| Hikma Pharmaceuticals USA | $184.27 | 2022-2025 | Ryaltris |
| Aerin Medical INC. | $164.73 | 2022-2025 | |
| Genentech USA, INC. | $150.46 | 2024 | Xolair |
| Blueprint Medicines Corporation | $134.12 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $114.30 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $82.34 | 2025 | Neffy |
| Acclarent, INC | $75.30 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $65.74 | 2020-2022 | |
| Smith+Nephew, INC. | $52.73 | 2019 | |
| Merck Sharp & Dohme LLC | $39.70 | 2023 | |
| Gilead Sciences, INC. | $36.91 | 2025 | |
| Integra Lifesciences Corporation | $32.90 | 2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Leo Pharma INC. | $28.88 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.79 | 2024 | Voquezna |
| Bard Access Systems, INC. | $26.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.11 | 2025 | Tezspire |
| Pfizer INC. | $23.56 | 2024 | |
| Aimmune Therapeutics, INC. | $22.73 | 2020 | |
| Paratek Pharmaceuticals, INC. | $21.79 | 2025 | Xhance |
| Photonicare INC | $21.57 | 2024 | Otosight Middle Ear Scope |
| Octapharma USA, INC. | $19.60 | 2021 | |
| Phadia US INC. | $19.37 | 2023 | Immunocap |
| Medtronic, INC. | $19.01 | 2024 | Propel |
| Intersect Ent, INC. | $18.68 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.66 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.09 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Allergan, INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Portnoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.